Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 2, 1996, Pages 125-131

  Remick, Scot C ^a   Chmura, Mary ^a   Bromberg, Cheryl ^a   Sporn, Jonathan ^a,b   Healey, Barbara ^a,c   Hilstro, Jane ^a,d   DeConti, Ronald C ^a,d   Horton, John ^a,d   Ruckdeschel, John C ^a,d   Harper, Gregory R ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c BASSETT MEDICAL CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; CONFIDENCE INTERVALS; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NAUSEA; NEUTROPENIA; REMISSION INDUCTION; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 9244241997     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199604000-00007     Document Type: Article

References (41)

1. Hayes DF, Henderson IC. CAF in metastatic breast cancer: standard therapy or another effective regimen? J Clin Oncol 1987;5: 1497-9.
2. Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. Etoposide and cisplatin as first-line therapy for small cell lung cancer. J Clin Oncol 1985;3:1471-7.
3. Evans WE, Osoba D, Feld R, Shepherd FA, Bazos MJ, DeBoer G. Etoposide and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 1985;3:65-71.
4. Hainsworth JD, Williams SD, Einhorn LH, Birch R, Greco FA. Successful treatment of resistant germinal neoplasms with etoposide and cisplatin: results of a Southeastern Cancer Study Group trial. J Clin Oncol 1985;3:666-71.
5. Achterrath W, Niederle N, Roetigg R, Hilgard P. Etoposide - chemistry, preclinical and clinical pharmacology. Cancer Treat Rev 1982;9:3-13.
6. Mabel JA, Little AD. Therapeutic synergism in murine tumors for combinations of cis-diamminedichloroplatinum with VP-16-213 or BCNU [Abstract]. Proc AACR ASCO 1979;20:230.
7. Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr. Cis-dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumor of mice. Cancer Treat Rep 1979;63:1459-73.
8. Corbett TH, Groswold DP, Roberts BJ, Peckham JC, Schabel FM. Biology and therapeutic response to a mouse mammary adenocarcinoma (16/c) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep 1978;62:1471-88.
9. Sledge GW Jr. Etoposide in the management of metastatic breast cancer. Cancer 1991;67:266-70.
10. Schell FC, Yap HY, Hortobagyi GN, Issell B, Esparza L. Phase II study of VP-16-213 (etoposide) in refractory metastatic breast carcinoma. Cancer Chemother Pharmacol 1982;7:223-5.
11. Vaughn CB, Panettiere F, Thigpen T, Bottomley R, Hoogstraten B, Samal B. Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group study. Cancer Treat Rep 1981;65:443-5.
12. Welsch CW. Effects of cis-platinum diamminedichloride-II on growth of 7, 12-dimethylbenzanthracene (DMBA)-induced mammary tumors in female rats [Abstract]. Proc AACR 1971;12: 25.
13. Wolpert-DeFilippes MK. Antitumor activity of cis-dichlorodiammineplatinum (II). Cancer Treat Rep 1979;63:1453-8.
14. Bull JM, Anderson T, Lippman ME, Cassidy JG, Gormley PE, Young RC. A phase II trial of cis-platinum II (cis-DDP) in breast and ovarian carcinomas [Abstract]. Proc ASCO 1978;19:87.
15. Calvo DB III, Patt YZ, Wallace S, et al. Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro-platinum (II) for regionally confined malignancy. Cancer 1980;45:1278-83.
16. Forastiere AA, Hakes TB, Wittes JT, Wittes RE. Cisplatin in the treatment of metastatic breast carcinoma. A prospective randomized trial of two dosage schedules. Am J Clin Oncol 1982;5: 243-7.
17. Yap HY, Salem P, Hortobagyi G, et al. Phase II study of cis-dichlorodiammineplatinum (II) in advanced breast cancer. Cancer Treat Rep 1978;62:405-8.
18. Sledge GW Jr, Loehrer PS, Roth BJ, Einhorn LH. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988;6: 1811-14.
19. O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE. Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med 1985;312:692-700.
20. Cavalli F, Sonntag R, Jungi F, Senn HJ, Brunner KW. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat Rep 1978;62:473-5.
21. Bennett CL, Sinkule JA, Schilsky RL, Senekjian E, Choi KE. Phase I clinical trial and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 1987;47:1952-6.
22. DeConti RC, Toftness BR, Lange RC, Creasey WA. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 1973;33:1310-15.
23. Gormley PE, Bull JM, Leroy AF, Cysyk R. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 1979;25: 351-7.
24. Drewinko B, Brown BW, Gottlieb JA. The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res 1973;33:3091-5.
25. Drewinko B, Gottlieb, JA. Action of cis-dichlorodiammineplatinum (II) (NSC-119875) at the cellular level. Cancer Chemother Rep 1975;59:665-73.
26. Sidgestad CP, Grdina DJ, Peters LF, Stutesman J. Cell cycle phase preferential killing of fibrosarcoma tumor cells by cis-dichlorodiammineplatinum or Adriamycin [Abstract]. Proc AACR 1979;20:178.
27. Harder HC, Rosenberg B. Inhibitory effects of anti-tumor platinum compounds on DNA, RNA, and protein synthesis in mammalian cells in vitro. Int J Cancer 1970;6:207-16.
28. Lokich JJ. Phase I study of cis-diamminedichloroplatinum (II) administered as a constant 5-day infusion. Cancer Treat Rep 1980;64:905-8.
29. Salem P, Khalyl M, Jabboury K, Hashimi L. Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity. Cancer 1984;53:837-40.
30. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
31. Creagan ET, Richardson RL, Kovach JS. Pilot study of a continuous five-day intravenous infusion of etoposide concomitant with cisplatin in selected patients with advanced cancer. J Clin Oncol 1988;6:1197-1201.
32. Earhart RH. Instability of dis-diamminedichloroplatinum in dextrose solution [Letter]. Cancer Treat Rep 1978;62:1105-6.
33. National Cancer Institute. Common toxicity criteria. Bethesda, Maryland: National Cancer Institute, 1988.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
35. Athanassiades P, Bacoyiannes H, Kontoyiannes D. Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy. Chemioterapia 1986;5:125-7.
36. Cox EB, Burton GV, Olsen GA, Vugrin D. Response of refractory breast carcinoma to a combination of cisplatin and etoposide [Abstract]. Proc ASCO 1986;5:64.
37. Cocconi G, Tonato M, DiCostanzo F, et al. Platinum and etoposide in chemotherapy refractory metastatic breast cancer: a phase II trial of the Italian Oncology Group for Clinical Research (GOIRC). Eur J Cancer Clin Oncol 1986;22:761-4.
38. Tinsley R, Fuks J, Korzun A, et al. Cisplatin and etoposide for advanced breast cancer: a phase II trial [Abstract]. Proc ASCO 1986;5:74.
39. Cocconi G, Bisagni G, DeLisi V, et al. Platinum (P) and etoposide (E) as a first-line chemotherapy (CT) for metastatic breast carcinoma (MBC) [Abstract]. Proc ASCO 1988;7:13.
40. Krook JE, Loprinzi CL, Schaid DJ, et al. Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer. A collaborative North Central Cancer Treatment Group/ Mayo Clinic phase II study. Cancer 1990;65:418-21.
41. Lokich J, Schulz J, Rosenthal CJ, Fryer J, Fryer D. Etoposide plus cisplatin by 72-hour infusion for non-small cell lung cancer. J Infusional Chemother 1993;3:28-31.